EndoBarrier® Therapy is the first endoscopically-delivered device therapy for people living with uncontrolled type 2 diabetes and obesity. EndoBarrier Therapy is a convenient and discreet treatment for people whose diabetes medications are no longer effective or who are at risk for serious health complications from diabetes and excess weight and who want to avoid surgery or the progression to injectable medications. This first-of-its-kind therapy is helping patients around the world fight their battle against type 2 diabetes and obesity while providing a pathway to a healthier lifestyle.
Clinical data suggest that treatment with EndoBarrier Therapy affects key gastrointestinal hormones involved in insulin sensitivity, glucose metabolism, satiety and food intake. Additionally, in clinical studies, EndoBarrier Therapy has also been shown to improve cardiometabolic risks.2,3 EndoBarrier is approved and commercially available in multiple countries outside the U.S.; and GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial) in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. If you are interested in learning more about the U.S. pivotal trial (The ENDO Trial), please visit www.endobarriertrial.com.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. EndoBarrier currently has the CE mark and is approved for commercial use in Australia, and a growing number of countries.
The most commonly reported complications are gastrointestinal in nature. They include nausea, vomiting and upper abdominal pain of mild to moderate severity and are most prevalent in the early days and weeks following EndoBarrier placement. Other uncommon risks include infection, trauma, device migration and bleeding, any of which may result in endoscopic or surgical removal of the device. As with all endoscopic and/or implant procedures, serious injury or death can occur.